ESMO 2024: Optimising the personalisation of prostate cancer treatment
ecancer reporter, Peter Goodwin, chairs a roundtable discussion with Dr John Mendelsohn (The University of Texas MD Anderson Cancer Center, Houston, USA), Dr Razelle Kurzrock (Moores Cancer Center, San Diego, USA) and Dr Mace Rothenberg (Pfizer Inc., New York, USA) about the goals of the WIN consortium and how these fields are highlighted at the annual WIN Symposium in Paris. Topics include personalised medicine, targeted molecules, and biomarkers in oncology.
The symposium will take place from the 23rd - 24th of June at the Marriott Rive Gauche Hotel in Paris, France.
ecancer members receive a discount on registration - login or join the ecancer club here.
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Choosing Wisely in radiology Tanzania
The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival
Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast cancer